To discuss currently available and emerging therapies in the treatment of sight-threatening non-infectious intermediate, posterior, and panuveitis.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.
Advanced in clinical and bench research in ophthalmology has produced multiple new treatment options for a variety of ocular diseases. New technology, including the fast growing field of ocular imaging, is been used to further understand eye anatomy and pathology. Progress in the field of ocular surgery has introduced new techniques and better outcomes. The clinical and research environment is complex; issues related to ethics, quality improvement and new technology affect all eye care providers. The Eye Institute has, as one of its mission, the goal of being at the forefront of research, clinical care and education. Our goal is to educate the academic and community eye care providers, residents, researchers and medical students on the best and newest clinical and surgical treatments, cutting edge research and important non-clinical topics available in the field.
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 1.00 hours of participation for continuing education for allied health professionals.
- To describe new treatment modalities in uveitis
- To discuss biologic drugs in the treatment of uveitis.
- To describe therapeutic agents and approaches currently in development.
All persons in control of content has no relevant financial relationships to disclose with the exception of:
Santen, Mallinckrodt, Inotek
Bristol Meyers Squibb, Genentech, EyeGate, Aldeyra, Clearside, pSivida, NEI/NIH
Researcher/ Site PI
Consultant (clinical trial steering committee) Researcher (local Site PI)
Consultant (including clinical trial steering committee, VISUAL studies, and global lead investigator, VISUAL III study); Researcher, (local site PI) and Speakers Bureau
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved